Nabil hydrochloride, a class 3.1 high blood pressure drug of Fuan Pharmaceutical Co., Ltd., entered the site for examination this month and is expected to be approved within this year

According to the information on the website of CFDA on June 12, the new chemical drug of Fuan Pharmaceutical (300194 SZ) category 3.1 will enter the drug registration and production site for inspection this month According to the drug review process, the product is expected to be approved within half a year It is worth mentioning that there are no domestic enterprises approved to produce Nabil hydrochloride, and Fu'an pharmaceutical products will become the first imitation after being put on the market According to the public information, Nabil hydrochloride is the third generation beta blocker developed by Johnson & Johnson, which is used to treat primary hypertension and mild to moderate stable chronic heart failure According to the Research Report of Guolian securities, in 2012, the global sales of Nabil hydrochloride reached US $1 billion, which is also a potential 1 billion product in the domestic market CFDA website information shows that at present, only Fu'an pharmaceutical and Jiangxi Qingfeng pharmaceutical have applied for the production approval of the product It is worth mentioning that at present, the products of Jiangxi Qingfeng Pharmaceutical Co., Ltd are in the stage of making inspection plan in the field inspection of drug registration production, and the progress is slightly slower than that of Fu'an Pharmaceutical Co., Ltd Fu'an pharmaceutical is mainly engaged in the production and sales of antibiotics, and is actively transforming to specialized drugs Nabil hydrochloride is one of the most important varieties under research.